Cargando...
Akt/mammalian target of rapamycin counteract the antitumor activities of cixutumumab an anti-insulin-like growth factor I receptor monoclonal antibody
Recent reports have shown limited anticancer therapeutic efficacy of insulin-like growth factor receptor (IGF-1R)-targeted monoclonal antibodies (mAbs), but the resistance mechanisms have not been completely identified. Because cooperation between epidermal growth factor receptor (EGFR) and IGF-IR c...
Gardado en:
| Main Authors: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2011
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3237768/ https://ncbi.nlm.nih.gov/pubmed/21980128 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-11-0235 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|